Which class of drugs does Daprodustat belong to and its position and characteristics among HIF-PH inhibitors?

Daprodustat (Daprodustat) belongs to the HIF-PH inhibitor class of drugs and is a new oral drug used in the treatment of chronic kidney disease anemia (CKD-Anemia) in recent years. Unlike traditional erythropoietin (ESA), daprostat does not directly supplement exogenous erythropoietin. Instead, it promotes the patient's own production of more stable and physiological erythropoietin-stimulating signals by regulating the hypoxia adaptation pathway in the body. It is positioned as a third-generation anemia drug and is one of the earlier approved representatives in the HIF-PHI camp. It has shown certain advantages in terms of safety and pharmacokinetics, so it has received more and more clinical attention.

From a mechanism perspective, daprostat mainly prevents the degradation of HIF-α by inhibiting prolyl hydroxylase (PHD) in the body, allowing it to stably exist in cells and enter the nucleus, activating the expression of genes related to hypoxia response. In this way, the drug promotes the natural production of erythropoietin in the body, enhances iron absorption and utilization, inhibits inflammation-related anemia mechanisms, and simultaneously improves multiple metabolic pathways required for red blood cell production. Compared with injectable ESA, its red blood cell production is closer to the circadian rhythm and is less prone to extreme erythropoietin peaks, so it is considered to have potential advantages in reducing cardiovascular risk. This is also one of the important reasons why daprostat has a higher positioning among HIF-PH inhibitors.

Among similar drugs, daporostat is often compared horizontally with roxadustat, vidalostat, etc.HIF-PHI. Its characteristics include more controllable metabolic processes, relatively smooth dosage adjustment, and less impact on inflammation, so it can show good adaptability in both dialysis and non-dialysis CKD patients. Studies have shown that after treatment with this drug, hemoglobin remains more stable, and some patients have improved iron utilization, eliminating the need for over-reliance on intravenous iron. More importantly, the oral administration mode of daprostat greatly improves the convenience of long-term treatment, making it more consistent with patient compliance needs in the long-term management of anemia in chronic kidney disease. Therefore, it has gradually become one of the most popular choices among HIF-PHI drugs.

In general, daporostat is a core member of the HIF-PH inhibitors, and is positioned as a "new generation, oral, mechanism-based multi-target modulation" anemia treatment drug. It not only improves anemia through a more natural red blood cell regulation pathway, but also shows better iron utilization and more convenient long-term medication in clinical practice. As more data accumulates, the drug has gradually become an important representative in the HIF-PHI camp, providing an alternative to traditional ESA for patients with anemia in chronic kidney disease.key new avenues for treatment.

Keyword tag:

Daprostat, HIF-PHinhibitor, anemia, chronic kidney disease, CKD, mechanism of action, roxadustat, efficacy comparison, clinical indications, safety

Reference materials:https://www.drugs.com/international/daprodustat.html